General Information


DRACP ID  DRACP06135

Peptide Name  

Sequence  CLDGGRPKC

Sequence Length  9

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Cancer targeted peptides Tumor-homing peptides Arsenic- containing anti-cancer agent



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic  Cyclic

Disulfide/Other Bond  Bridging: Cys1<---As--->Cys9

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C37H65N13O12S2

Absent amino acids  AEFHIMNQSTVWY

Common amino acids  CG

Mass  109101

Pl  8.23

Basic residues  2

Acidic residues  1

Hydrophobic residues  1

Net charge  1

Boman Index  -1983

Hydrophobicity  -61.11

Aliphatic Index  43.33

Half Life 
  Mammalian: 1.2 hour
  Yeast: >20 hour
  E.coli: >10 hour

Extinction Coefficient cystines  125

Absorbance 280nm  15.63

Polar residues  4

Amino acid distribution



Literature Information


Literature 1

Pubmed ID Not available

Title  Not available

Doi Not available

Year  Not available

Patent

Patent ID CN111344298A

Patent Title  Anti-cancer agent

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.